Oncology and Carcinogenesis articles for Peking University (PKU), China

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 192

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
7 4.48
Reprogramming Postablation Tumor Immune Microenvironment with Dual-Function Nanotherapeutic Immunomodulator for Synergistic Antitumor Immunity and Recurrence Suppression 1.00
A Recombinant Targeted Bionanoparticle In Vitro Expressing a Gene-Editing Protein for Epidermal Growth Factor Receptor Mutant Lung Cancer 0.75
Senescence-Primed Ferroptosis Enabled by a Metal–Organic Framework Nanoplatform for Enhanced Cancer Therapy 1.00
Ultrasound-Mediated Piezocatalysis Triggers NO Release to Augment Targeted Immunotherapy of Pancreatic Cancer 0.50
Hybrid-Ligand Metal–Organic Frameworks Enabling Radio–Radiodynamic–Chemodynamic Therapy Primes Checkpoint Blockade Immunotherapy in Hypoxic Tumors 0.90
Machine Learning-Assisted Multimodal Early Screening of Lung Cancer Based on a Multiplexed Laser-Induced Graphene Immunosensor 0.07
A Wireless Cytosensor Based on a Bionic Dandelion Isothermal Amplification System for Ultrasensitive Detection of Circulating Tumor Cells 0.26
4 2.14
A pH-responsive polymeric nanovaccine with efficient endosomal escape and potent antitumor immunity for cancer treatment 1.00
Fluorinated Polymeric Nanoplatform Relieves Tumor Hypoxia and Enhances Chemo-Sonodynamic Therapy 0.84
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2− breast cancer: The LINUXtrial 0.04
Targeted nanosensitizer-augmented sono-immunotherapy with STING agonist to remodel the immune microenvironment in hepatocellular carcinoma 0.25
4 1.24
Chiral Au@Ag Nanoparticles Regulate Macrophage Reprogramming for Enhanced Anti-Tumor Efficacy 0.90
Engineering of 2D Ultrathin CuS-PMA Heterostructures for Enhanced NIR-II Photothermal Therapy Facilitating Oxidative Stress and Immunotherapy 0.14
X‐Ray‐Activated Self‐Calibrating Second Near‐Infrared Fluorescent Probes for Precision Radiosensitization Therapy in Esophageal Cancer 0.17
Amplifying ER Stress via Biodegradable Pseudo-Conjugated Polymer Nanoparticles for Enhanced Sonodynamic Immunotherapy 0.03
11 2.74
Bone-Targeted Nanoparticles Enable Metabolic Reprogramming via cGAS Lactylation Suppression to Restore Chemosensitivity and Antitumor Immunity in Osteosarcoma 0.09
G-Quadruplex-Modular CpG Nanoplatform Drives Multi-Pathway Immunity for Abscopal Chemoimmunotherapy 0.34
An Antigen-Capturing Nanoparticle Harnesses the Protein Corona to Enhance Antigenic Immunogenicity and Clonal Diversity against Cancer 0.11
A New Strategy for Controlled In Situ Release of IL-2 from Tumor Spheroids Using a NIR-II Light-Mediated Optogenetic Manipulation System 0.34
NIR-II Photoactivatable Cobalt(III) Nanoparticles for Photoactivated Metal Chemo-Immunotherapy 0.50
Microwave-Actuated Hot-Carrier/Polarization Triggers Catalysis to Coordinate Staphylococcus aureus Ribosome Stalling and Treat Deep-Seated Infections 0.34
Polymer‐PARPi Conjugates Delivering USP1i for Maximizing Synthetic Lethality to Stimulate STING Pathway in High‐Grade Serous Ovarian Cancer 0.04
Defect Engineering‐Driven Electron Spin Polarization and Charge Transfer in MOFs for Enhanced Sonocatalytic Therapy 0.02
Nanozyme‐Based Biomimetic Intelligent Immune Organelles for the Treatment of Bladder‐Metastasized Tumors 0.07
Personalized 3D Vaccine Integrates Immunotherapy and Antiangiogenic Therapy to Prevent Oral Squamous Cell Carcinoma Recurrence 0.10
Engineering a Lipid Nanoparticle with Atypical Calcium Crystal Structure for Enhanced IFNβ‐Mediated Immunotherapy 0.78
1 0.97
Extremely early genomic events and temporal order of esophageal squamous cell carcinogenesis: Longitudinal self-comparison of progressors and non-progressors 0.97
1 0.05
A trans-omics gene-smoking interaction study of lung cancer based on consortium data 0.05
5 0.93
Point-of-Care Detection of Dual Methylation Genes for Rapid Bladder Cancer Diagnosis and Prognosis 0.36
Development of an Aptamer/CRISPR-Cas12a-Based Dual-Modal Biosensor for Fusobacterium nucleatum Detection in Non-Invasive Colorectal Cancer Screening 0.08
Deciphering the Mechanism of Interactions between Polyubiquitin Chains and Caspase Activation and Recruitment Domains Using Protein–Polymer-Engineering-Assisted Native Mass Spectrometry 0.10
First Fluorescent Probe for TREX1 Enables Real-Time Tracking of DNA Repair and Immune Regulation in Cancer Cells 0.33
Dual-Modulation Design to Develop ER-Targeting NIR Pyroptosis Inducers with Type I PDT Efficacy and Amplified Antitumor Immunity 0.06
1 0.11
Au6Cu2 Clusters with High Electron Affinity and Oxygen-Mimetic Properties for Hypoxic Tumor Radiosensitization 0.11
1 0.74
Heterogeneous responses of IM19 anti-CD19 CAR T-cell therapy in refractory systemic lupus erythematosus: an open-label pilot study and a mini-review 0.74
1 0.08
Preclinical characterization of TGRX-678, a brain-penetrant allosteric inhibitor of BCR::ABL1 0.08
1 0.10
Deep learning analyses of splicing variants identify the link of PCP4 with amyotrophic lateral sclerosis 0.10
8 0.91
JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial 0.03
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial 0.01
Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant immunochemotherapy in gastric cancer 0.04
Single-cell screens identify ADAM12 as a fibroblast checkpoint impeding anti-tumor immunity 0.31
Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer 0.01
Remodeling of T and endothelial cells during total neoadjuvant therapy in rectal cancer 0.31
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study 0.09
Integrated single-cell and spatial transcriptomics uncover distinct cellular subtypes involved in neural invasion in pancreatic cancer 0.13
7 2.03
AKT3-Driven Epithelial–Mesenchymal Plasticity Governs Ovarian Metastasis in Colorectal Cancer via Tumor Microenvironment Remodeling 0.65
Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression 0.23
NRF1 Induces ApoEhigh Cancer-Associated Fibroblasts to Promote Stemness of Renal Cell Carcinoma 0.19
LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer 0.11
RORγ Hijacks HIF-1α to Promote Peritoneal Metastasis of Gastric Cancer. 0.06
SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts. 0.75
Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy 0.05
3 0.16
Rational discovery of therapeutic PAK1 allosteric activators 0.02
Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy 0.14
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis 0.00
2 0.05
Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS-driven AML 0.02
Arachidonic acid triggers spermidine synthase secretion from primary tumor to induce skeletal muscle weakness upon irradiation 0.03
2 0.35
Paired patient-derived organoids reveal transcription factor-driven epigenetic remodeling in breast cancer metastasis 0.02
An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer 0.33
2 0.87
Lighting up the linear ubiquitin code: a bioluminescent sensor for M1-specific deubiquitinase activity and drug discovery 0.79
A matrix metalloproteinase-responsive iridium(iii)-based hydrogel for cancer cell-specific imaging and lysosome-targeted photodynamic therapy 0.08
2 0.55
Unleashing T cell surveillance for the eradication of quiescent persister tumor cells resistant to neoadjuvant chemotherapy 0.02
Cloche/Npas4l is a pro-regenerative platelet factor during zebrafish heart regeneration 0.54
2 1.08
Integrated Evidence for Lysosomal Dysfunction-Mediated Iron Dysregulation induced by PM2.5 Exposure 0.98
Profiling the Chemical Exposomic Landscape of Esophageal Squamous Cell Carcinoma 0.10
1 0.05
Breast tumour-secreted ADAM10 mediates atrial fibrogenesis and fibrillation 0.05
1 0.63
Cancer driver topologically associated domains identify oncogenic and tumor-suppressive lncRNAs 0.63
8 1.61
Hypoxia-related and immune phenotype-related fusion model for non-invasive prognostication of hepatocellular carcinoma treated by TACE: a multicentre study 0.02
Prospective evaluation of radical surgery for adenocarcinoma of oesophagogastric junction: real-world insights from the CLAEG study 0.05
Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics 0.46
KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy 0.03
Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study 0.05
KIF1Bβ suppresses hepatocellular carcinoma by transporting and secreting FBLN5 to attenuate the integrin pathway 0.09
Bacteroides intestinalis mediates the sensitivity to irinotecan toxicity via tryptophan catabolites 0.21
NLRP6 deficiency enhances macrophage-mediated phagocytosis via E-Syt1 to inhibit hepatocellular carcinoma progression 0.70
2 0.24
O-GlcNAcylation of the tumor suppressor LATS1 drives mitotic progression via PLK1 0.20
Structural insights into the substrate transport mechanism of the amino acid transporter complex 0.04
4 0.50
HER2 deficiency causes a developmental disorder with growth retardation and craniofacial malformations 0.20
Proteogenomic characterization of cervical cancer identifies molecular subtypes predictive of clinical outcomes and subtype-specific targets 0.03
Non-canonical functions of UGT2B17 promote castrate-resistant prostate cancer progression 0.06
ZEB1 promotes chemo-immune resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL16 0.21
5 0.19
Randomized Parallel-Group Phase II Study (NEOTERIC) of Atezolizumab With or Without Tiragolumab After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. 0.08
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). 0.02
Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study. 0.03
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer. 0.01
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study. 0.05
1 0.06
Membrane-IL12 adjuvant mRNA vaccine polarizes pre-effector T cells for optimized tumor control 0.06
1 0.01
Neddylation E1 obligatory subunit Nae1 is critical to neuromuscular junction development and maintenance 0.01
1 0.08
Pathologic complete response after neoadjuvant immunochemotherapy: Persistent recurrence risk highlights the need for stratified management 0.08
2 0.04
Discovering Targetable Conformation of RhoA Mutant by Integrating Native Mass Spectrometry, Ultraviolet Photodissociation, and X-ray Diffraction 0.00
Development of Substrate-Directed Activity-Based Probes via Disulfide-Trapping for Site-Specific Interrogation of Nucleosomal Deubiquitination 0.04
2 0.30
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers 0.00
Prospective associations of diabetes with 15 cancers in 2.2 million UK and Chinese adults 0.29
1 0.10
HIF-independent oxygen sensing via KDM6A regulates ferroptosis 0.10
2 1.06
Synergistic Nucleus-Targeting Photodynamic Therapy and DNA Repair Inhibition to Activate Innate and Adaptive Antitumor Immunity for Amplifying Photoimmunotherapy 0.80
Synergistic Defect-Driven Chemocatalysis and Ultrasound-Activated Piezocatalysis by Two-Dimensional SnSe Nanosheets 0.26
3 1.03
Cell-free chromatin state tracing reveals disease origin and therapy responses 0.66
Activated ATF6α is a hepatic tumour driver restricting immunosurveillance 0.00
Intratumoural vaccination via checkpoint degradation-coupled antigen presentation 0.36
3 0.72
Unique gluing effect of ASXL1 K351 monoubiquitination stimulates the PR-DUB activity 0.33
Structural basis for E4 enzyme Ufd2-catalyzed K48/K29 branched ubiquitin chains 0.32
In situ proximity labeling of proteins associated with circRNA and RNA G-quadruplexes 0.07
36 10.55
Caspase-4 transgenic mice exhibit cytoplasmic TDP-43 accumulation and age-dependent neuropathology 0.11
A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma 0.96
Arid3b suppresses CD8 + T cell infiltration and function in microsatellite-stable colorectal cancer via Runx3 0.75
The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial 0.33
HuR coordinates systemic aging through platelet infiltration 0.38
Augmented prediction of multi-species protein–RNA interactions using evolutionary conservation of RNA-binding proteins 0.13
Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer 0.06
A cell cycle-dependent transition of acetylation to phosphorylation regulates timely centrosome maturation 0.11
Engineering programmable CAR and antigen pairing via drug-gated light activation 0.05
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial 0.03
Molecular insights into mRNA export regulation by the human TREX-2 complex 0.11
Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer 0.20
Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC 0.20
cfGWAS reveal genetic basis of cell-free DNA end motifs 0.01
Amelioration of colorectal cancer-associated fibroblasts in immunosuppressive microenvironment by ferroptosis-based nanotherapy 0.91
Paclitaxel drives TREM2 macrophage expansion underlying its inferior therapeutic efficacy compared to Nab-paclitaxel 0.48
An interpretable AI system reduces false-positive MRI diagnoses by stratifying high-risk breast lesions 0.03
NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial 0.03
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS) 0.06
Boron neutron capture therapy preserves immune cells and induces robust anti-tumour immunity in preclinical mouse model 0.26
Metabolic syndrome promotes endometrial cancer by Oleic acid-mediated polyamine accumulation 0.98
USP29 and SMURF1 orchestrate FSP1-mediated ferroptosis suppression to facilitate chemoresistance in gastric cancer 0.04
Lypd6b depletion promotes CD8+ T cell-mediated anti-tumor immunity via metabolic reprogramming in colorectal cancer 0.13
Molecular mechanism of PINK1 regulation by the Hsp90 machinery 0.23
Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study 0.60
Structural basis for transport and inhibition of the human glucose-6-phosphate transporter G6PT 0.14
FAP+ fibroblasts orchestrate tumor microenvironment remodeling in renal cell carcinoma with tumor thrombus 0.09
A next-generation anti-CTLA-4 probody mitigates toxicity and enhances anti-tumor immunity in mice 0.16
CXCR4 mediated recognition of HIV envelope spike and inhibition by CXCL12 0.37
GD2T cells as a platform for single-dose and long-term delivery of biologics 0.14
Molecular landscape, subtypes, and therapeutic vulnerabilities of central nervous system solitary fibrous tumors 0.17
STN1 facilitates metastasis by promoting transcription of EMT-activator ZEB1 in pancreatic cancer 0.97
Structural insights into cholesterol sensing by the LYCHOS-mTORC1 pathway 0.95
Orchestrating intratumoral DC-T cell immunity for enhanced tumor control via radiotherapy-activated TLR7/8 prodrugs in mice 0.19
Single atom engineering for radiotherapy-activated immune agonist prodrugs 0.18
TIM3-blockade synergizes with IL2 in alleviating intra-tumoral CD8T cell exhaustion 0.03
2 0.04
Global multi-ancestry genome-wide analyses identify genes and biological pathways associated with thyroid cancer and benign thyroid diseases 0.01
Single-cell multi-omic and spatial profiling of esophageal squamous cell carcinoma reveals the immunosuppressive role of GPR116+ pericytes in cancer metastasis 0.02
1 0.95
In situ-generated vaccine-like pyroptosome for personalized cancer immunotherapy 0.95
7 0.91
Global and regional cancer burden attributable to modifiable risk factors to inform prevention 0.02
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial 0.04
Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial 0.01
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial 0.04
CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial 0.05
The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial 0.06
A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial 0.68
1 0.78
Structural basis of G6P/Pi transport and inhibition in SLC37A4 0.78
1 0.12
6-Hydroxydopamine promotes antitumor immunity through macrophage remodeling beyond sympathetic ablation 0.12
1 1.00
Methylation of RBM39 by PRMT6 enhances resistance to Indisulam in non-small cell lung cancer by promoting alternative splicing of proto-oncogenes 1.00
4 1.68
Mitochondrial fusion heterogeneity drives bidirectional tumor phenotypic transition in combined hepatocellular–cholangiocarcinoma 0.32
A CHKA–PML autophagy checkpoint enables tumors to evade glutamine starvation 0.19
Deubiquitinase OTULIN dampens RIG-I-dependent antiviral signaling by removing linear ubiquitination from TRAF6 1.00
TROP2-targeted NIR-II fluorescence imaging for visualizing surgical margins and metastatic sentinel lymph nodes in breast cancers 0.17
2 0.69
MRI-based Habitat Analysis for the Prediction of Progression-Free Survival in Primary Spinal Tumors. 0.60
Mesorectal Fascia Involvement by Tumor Deposits or Extramural Vascular Invasion at MRI Predicts Prognosis in Rectal Cancer. 0.09
2 0.38
Dynamic U2AF cycling defines two phases of cotranscriptional pre-mRNA splicing 0.12
Structural basis of BAX pore formation 0.27
6 1.35
Genome-wide screenings identify BAP1 as a synthetic-lethality target with CDK4/6 inhibitors 0.23
STING stimulation via supramolecular prodrug hydrogel boosts innate-adaptive immune cross-talk to prevent glioblastoma recurrence 0.11
Targeting RRM2 with dual-modal theranostic smart nanoresponder overcomes osimertinib resistance and triggers immune remodeling in NSCLC 0.46
USP13 stabilizes NLRP3 to facilitate inflammasome activation by preventing TRIM31-mediated NLRP3 ubiquitination and degradation 0.10
RNA binding protein DDX3X drives pancreatic cancer progression via the TLE2-MYL9 axis 0.03
Molecular and neural basis of vomiting behavior in Drosophila melanogaster 0.42
4 0.25
Phase separation–based HTS identifies cobimetinib as a YAP-TEAD inhibitor that suppresses hyperactivated YAP-induced cancer progression 0.02
In vivo generation of CAR myeloid cells through erythrocyte-mediated mRNA delivery for cancer immunotherapy 0.11
A hyperactive splice variant of STAT3 promotes colonic inflammation-associated tumorigenesis in mice 0.11
Proteogenomic characterization reveals that lipid droplet formation promotes esophageal squamous cell cancer progression 0.01
3 0.15
Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial 0.03
Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial 0.06
Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial 0.05
1 0.94
Structures of the neutral amino acid transporter LAT4 provide insights into antitumor effects of its inhibitor tubeimoside-1 0.94
3 0.18
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial 0.03
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial 0.02
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial 0.13
7 1.03
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB–IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study 0.04
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial 0.11
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study 0.08
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial 0.07
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial 0.12
Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis 0.56
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial 0.05
9 0.35
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations 0.03
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer 0.03
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer 0.03
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma 0.02
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC 0.03
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer 0.13
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.03
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer 0.01
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer 0.03

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.